Sanofi drops pursuit of eczema drug amlitelimab after failed Phase 3 trials
Sanofi announced it will no longer seek regulatory approval for amlitelimab, an anti‑OX40 ligand antibody intended for atopic dermatitis, after recent Phase 3 data fell short of expectations.
The drug was acquired in Sanofi’s $1.1 billion purchase of Kymab in 2021, but a September 2025 trial missed analyst expectations despite meeting primary endpoints, and a January 2026 study also failed to achieve key secondary measures.
The decision comes amid leadership changes, with former CEO Paul Hudson replaced by Belén Garijo, who is reshaping R&D and has installed new executives to steer the portfolio.
Sanofi said it will still evaluate the totality of data for possible future actions, but for now the company is ending its pursuit of amlitelimab for eczema.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that